Bemazumab is a monoclonal antibody targeting FGFRb
Posted: Mon Feb 17, 2025 8:59 am
After early accumulation, the company has entered the stage of dualline development of "external introduction + independent research and development", and its subsequent products are full of potential:
The company is expected to submit a marketing application to NMPA in . In the phase II clinical FIGHT study, bemazumab combined with chemotherapy was used as the firstline treatment for patients with gastric or gastroesophageal junction tumors with FGFRb overexpression, showing improvements in mPFS median progressionfree survival and mOS median progressionfree kuwait phone number list survival. Bemazumab has previously received FDA breakthrough therapy certification and is expected to become a new treatment option for patients with gastric cancer that overexpresses FGFRb.
. KarXT is a combination drug with an innovative mechanism for the treatment of schizophrenia. It was approved for marketing by the FDA in September , becoming the first innovative drug approved for the treatment of schizophrenia in years without the common black box warnings. It is expected that a marketing application for schizophrenia will be submitted to NMPA in early . KarXT has demonstrated good efficacy and safety in clinical practice, and is expected to solve the problem of low treatment compliance caused by the poor safety of antipsychotic drugs.
The company is expected to submit a marketing application to NMPA in . In the phase II clinical FIGHT study, bemazumab combined with chemotherapy was used as the firstline treatment for patients with gastric or gastroesophageal junction tumors with FGFRb overexpression, showing improvements in mPFS median progressionfree survival and mOS median progressionfree kuwait phone number list survival. Bemazumab has previously received FDA breakthrough therapy certification and is expected to become a new treatment option for patients with gastric cancer that overexpresses FGFRb.
. KarXT is a combination drug with an innovative mechanism for the treatment of schizophrenia. It was approved for marketing by the FDA in September , becoming the first innovative drug approved for the treatment of schizophrenia in years without the common black box warnings. It is expected that a marketing application for schizophrenia will be submitted to NMPA in early . KarXT has demonstrated good efficacy and safety in clinical practice, and is expected to solve the problem of low treatment compliance caused by the poor safety of antipsychotic drugs.